

# Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs

NCT07384013

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	Rambam Health Care Campus
Enrollment	30 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Adult oncology patients (≥18 years old).
- Receiving apixaban or rivaroxaban for anticoagulation.
- New/current metamizole users taking at least 1g TID for pain management.
- Platelets  $\geq 100 \times 10^9/L$
- ECOG PS  $\leq 3$

... and 1 more (see full listing online)

### Exclusion (2)

- History of allergic reaction to metamizole or DOACs.
- Individuals with significant gastrointestinal disorders that may affect absorption, including (but not limited to) diagnosed bowel obstruction, persistent diarrhea, or the presence of a nasogastric tube (NGT/zonda)

## Locations (1 total)

---

Rambam Health Care Campus, Haifa, Israel